Siliq

Chemical Namebrodalumab
Dosage FormInjection (subcutaneous; 210 mg/1.5 ml)
Drug ClassMonoclonal antibodies
SystemSkin
CompanyValeant Pharmaceuticals North America LLC
Approval Year2017

Indication

  • To treat moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy and are not currently responding to other systemic therapies.
Last updated on 11/13/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Siliq (brodalumab) Prescribing Information 2017Valeant Pharmaceuticals North America LLC, Bridgewater, NJ
Document TitleYearSource
Systematic review on rapidity of onset of action for interleukin-17 and interleukin-23 inhibitors for psoriasis. 2020Journal of the European Academy of Dermatology and Venereology
Short-term effectiveness of biologics in patients with moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis. 2020Journal of Dermatological Science
Short-term efficacy and safety of IL-17, IL-12/23, and IL-23 inhibitors brodalumab, secukinumab, ixekizumab, ustekinumab, guselkumab, tildrakizumab, and risankizumab for the treatment of moderate to severe plaque psoriasis: A systematic review and network meta-analysis of randomized controlled trials.2019Journal of Immunology Research
Long-term efficacy of novel therapies in moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis of PASI response.2019Journal of the European Academy of Dermatology and Venereology
Assessing the relative efficacy of interleukin-17 and interleukin-23 targeted treatments for moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis of PASI response. 2019PLoS One
Comparative effectiveness of targeted immunomodulators for the treatment of moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis. 2018Journal of the American Academy of Dermatology
The comparative efficacy of brodalumab in patients with moderate-to-severe psoriasis: a systematic literature review and network meta-analysis. 2018The Journal of Dermatological Treatment
A systematic review and meta-analysis of the efficacy and safety of the interleukin (IL)-12/23 and IL-17 inhibitors ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab and tildrakizumab for the treatment of moderate to severe plaque psoriasis. 2017The Journal of Dermatological Treatment
Systemic pharmacological treatments for chronic plaque psoriasis: A network meta-analysis. 2017The Cochrane Database of Systematic Reviews
Safety and efficacy of brodalumab for moderate-to-severe plaque psoriasis: A systematic review and meta-analysis. 2017Clinical Drug Investigation
Document TitleYearSource
Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. 2019Journal of the American Academy of Dermatology